The guidelines describe FDA-approved and off-label uses of bedaquiline in populations with multidrug-resistant tuberculosis that were not included in clinical trials. 

The European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) agrees with the World Health Organization (WHO) dosing recommendations for ethambutol, isoniazid, pyrazinamide, and rifampicin as first-line antituberculosis medicines used in children, according to new EMA dosing guidelines released February 17.